Floatz logo

Mesna

Acute Undifferentiated Leukemia

Ossium Health, Inc.Small moleculePhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
89/ 100

Competitive context

32 Active assets in the Acute Undifferentiated Leukemia cohort.

Asset / SponsorPhaseRating
Fludarabine
Fred Hutchinson Cancer Center
Phase 2BB
VINCRISTINE SULFATE
M.D. Anderson Cancer Center
Phase 3BB
Cytosin-Arabinosid
Fred Hutchinson Cancer Center
Phase 3BB
Cyclophosphamide
Masonic Cancer Center, University of Minnesota
Phase 3BB
METHOTREXATE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BB

View all 50 →

Same molecule, other indications

Mesna is also rated in:

Hodgkin's LymphomaDormant
BB
Indicative ·
69 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
BB
Indicative ·
69 / 100
View asset →
NK/T-cell LymphomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →